Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance

Basit Öğe Kaydı
dc.authoridmirian, mina/0000-0002-9322-2707
dc.authoridTabatabaee, Aliye/0000-0002-9240-7662
dc.authorwosidmirian, mina/F-3134-2018
dc.contributor.authorTabatabaee, Aliye
dc.contributor.authorNafari, Behjat
dc.contributor.authorFarhang, Armin
dc.contributor.authorHariri, Amirali
dc.contributor.authorKhosravi, Arezoo
dc.contributor.authorZarrabi, Ali
dc.contributor.authorMirian, Mina
dc.date.accessioned2024-05-19T14:50:21Z
dc.date.available2024-05-19T14:50:21Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractThis comprehensive review explores vimentin as a pivotal therapeutic target in cancer treatment, with a primary focus on mitigating metastasis and overcoming drug resistance. Vimentin, a key player in cancer progression, is intricately involved in processes such as epithelial-to-mesenchymal transition (EMT) and resistance mechanisms to standard cancer therapies. The review delves into diverse vimentin inhibition strategies. Precision tools, including antibodies and nanobodies, selectively neutralize vimentin's pro-tumorigenic effects. DNA and RNA aptamers disrupt vimentin-associated signaling pathways through their adaptable binding properties. Innovative approaches, such as vimentin-targeted vaccines and microRNAs (miRNAs), harness the immune system and post-transcriptional regulation to combat vimentin-expressing cancer cells. By dissecting vimentin inhibition strategies across these categories, this review provides a comprehensive overview of anti-vimentin therapeutics in cancer treatment. It underscores the growing recognition of vimentin as a pivotal therapeutic target in cancer and presents a diverse array of inhibitors, including antibodies, nanobodies, DNA and RNA aptamers, vaccines, and miRNAs. These multifaceted approaches hold substantial promise for tackling metastasis and overcoming drug resistance, collectively presenting new avenues for enhanced cancer therapy.en_US
dc.description.sponsorshipVice-presidency for Research of Isfahan University of Medical Sciences, Isfahan [3400778, 199438]en_US
dc.description.sponsorshipThe authors appreciate the financial support of the Vice-presidency for Research of Isfahan University of Medical Sciences, Isfahan (Grant No. 3400778 and 199438).en_US
dc.identifier.doi10.1007/s10555-023-10154-7
dc.identifier.issn0167-7659
dc.identifier.issn1573-7233
dc.identifier.pmid38012357en_US
dc.identifier.scopus2-s2.0-85178355176en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.1007/s10555-023-10154-7
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5677
dc.identifier.wosWOS:001107128400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer and Metastasis Reviewsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectVimentinen_US
dc.subjectMetastasisen_US
dc.subjectPlasticityen_US
dc.subjectDrug Resistanceen_US
dc.subjectInhibitoren_US
dc.subjectEmten_US
dc.titleTargeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistanceen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu